Effect Of PPAR-α Agonist On Inflammation Of Vascular Smooth Muscle Cells Induced By OxyHb

Objective To study the effect of peroxisome proliferator activated receptor alpha (PPAR-α) agonist fenofibrate-- and its specific inhibitor GW6471 on cerebral vasospasm in a rat subarachnoid hemorrhage (SAH) model.Methods using 100-120g SD rats under sterile conditions, the interception of thoracic aortic medial layer of the vessel wall cells, separation, the adherent cultured vascular smooth muscle cells,4-6 generation, identification of vascular smooth muscle cells by -SMC-actin staining, selecting qualified cell model. The cells were divided into control group, OxyHb group (10uM OxyHb), fenofibrate group 1 (OxyHb 1H 100uM fenofibrate before intervention to 2 groups (OxyHb), Fenofibrate Intervention 0.5h joined the 100uM fenofibrate), GW1 group (GW6471 pre blocking fenofibrate group 1), GW2 group (GW6471 pre blocked the fenofibrate group 2), give OxHb and related factors were after 48h incubation, cells after centrifugation to charge cell supernatant was detected by ELISA, the expression of TNF-α, each cell factor IL-1 beta.Results The results indicated that OxyHb group, TNF-α, IL-1β expression increased significantly compared with the control group, fenofibrate group 1,2 groups after Fenofibrate Intervention could obviously inhibit the expression of cytokines, and give the blockade of GW6471 cytokine specific expression of PPAR-α after the rise again. Suggesting that in vitro SAH model PPAR- alpha agonist fenofibrate can significantly decrease the expression of inflammatory cytokines in vascular smooth muscle cells, and the effect can be GW6471 specific blocked.Conclusion In vitro SAH model, OxyHb expression of cytokines in vascular smooth muscle cells in group TNF-α, IL-1β increased significantly compared with the control group, and give the PPAR-alpha agonist fenofibrate can significantly reduce the expression of inflammatory cytokines in the induction of OxyHb before or after induction, and the effect can be PPAR-alpha inhibitor GW6471 specific blocking. Vascular protective effect in vitro validation PPAR-alpha agonist fenofibrat.